Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shot up 3.5% on Monday . The stock traded as high as $11.95 and last traded at $11.80, with a volume of 247,775 shares. The stock had previously closed at $11.40.

Several research firms recently weighed in on VNDA. Brean Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 27th. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $14.00 price objective for the company in a research report on Tuesday. Jefferies Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Sunday, May 29th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating and set a $16.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday, July 28th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Vanda Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $16.83.

The stock’s 50-day moving average is $11.27 and its 200-day moving average is $9.37. The stock’s market capitalization is $516.38 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.12. During the same period last year, the business posted ($0.13) EPS. The firm earned $36.02 million during the quarter, compared to analysts’ expectations of $36.03 million. The company’s revenue was up 30.6% compared to the same quarter last year. On average, analysts expect that Vanda Pharmaceuticals Inc. will post ($0.61) EPS for the current fiscal year.

A hedge fund recently raised its stake in Vanda Pharmaceuticals stock. Bank of Montreal Can increased its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 23.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,208,918 shares of the biopharmaceutical company’s stock after buying an additional 228,074 shares during the period. Bank of Montreal Can owned about 2.82% of Vanda Pharmaceuticals worth $11,255,000 at the end of the most recent quarter.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.